RAASi is the foundational therapy for patients with heart failure and/or chronic kidney disease. But when these patients experience episodes of hyperkalemia RAASi therapy is often down-titrated or discontinued. In this program, a multidisciplinary faculty discusses how to navigate hyperkalemia in patients with cardiorenal disease.
This course consists of 3 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.
This educational program consists of 3 presentations on navigating hyperkalemia in patients with cardiorenal disease.
Challenges of managing hyperkalemia in patients with cardiorenal disease while maintaining RAASi therapy – Gianluigi Savarese, MD, PhD – Stockholm, Sweden
Implementing the latest evidence on novel potassium binders for achieving long term goals – Aaron Wong, MD – Bridgend, Wales, UK
Optimizing clinical care in patients with cardiorenal disease for achieving long term goals – Clara Bonanad Lozano, MD, PhD – Valencia, Spain and James Burton, MD – Leicester, UK
This activity has been designed to meet the educational needs of cardiologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with cardiorenal disease and hyperkalemia events.
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and MEDCON International. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for .75 number of credits. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until July 16, 2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for .75 contact hour/0.075 CEUs of pharmacy contact hours. The Universal Activity Number for this program is JA0006235-0000-24-082-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC) for 40 minutes of effective education time.
Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-CME.
Release Date:
Expiration Date:
